Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder

References

• Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009;373(9682):2223–2233. doi:10.1016/S0140-6736(09)60746-7
   PubMed Web of Science ®Google Scholar
• Valbuena A, Largo R, Quintero- Gutiérrez J, García- Resa E, Correas J. Comorbidity in hospitalized patients. Clinical and socio-health implications. Addictions. 2001;13(3):297–304.
   Google Scholar
• American Psychiatric Association –APA. DSM-5. Diagnostic and Statistical Manual of Mental Disorders. Madrid: Panamericana; 2014.
   Google Scholar
• Landa N, Fernández- Montalvo J, López- Goñi J, Lorea I. Psychopathological comorbidity in alcoholism: a descriptive study. Int J Clin Health Psychol. 2006;6(2):253–269.
   Web of Science ®Google Scholar
• Scherbaum N, Specka M. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res. 2008;17(S1):39–44. doi:10.1002/mpr.244
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–1943. doi:10.1001/jama.280.22.1936
   PubMed Web of Science ®Google Scholar
• NIDA. References. National Institute on Drug Abuse website; 2020. Available from: https://www.drugabuse.gov/nidamed-medical-health-professionals/treatment/opioid-use-disorder-treatment. Accessed December 30, 2020.
   Google Scholar
• Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(5051):1445–1452. doi:10.15585/mmwr.mm655051e1
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global status report on alcohol and health; 2018. Available from: http://www.infocoponline.es/pdf/alcohol-salud.pdf. Accessed December 30, 2020.
   Google Scholar
• Balcells M, Gual A. Pharmacotherapy of alcohol withdrawal. New drugs, new concepts. Addictions. 2002;14(1):439–448.
   Google Scholar
• Kjome KL, Moeller FG. Long-acting injectable naltrexone for the management of patients with opioid dependence. Subst Abuse. 2011;5:1–9. doi:10.4137/SART.S5452
   PubMedGoogle Scholar
• Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psycho-social interventions to treat opioid addiction. Clin Psychol Rev. 2010;30:155–166. doi:10.1016/j.cpr.2009.10.006
   PubMed Web of Science ®Google Scholar
• Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence (Review). Cochrane Database Syst Rev. 2010;(12). doi:10.1002/14651858.CD001867.pub3
   Web of Science ®Google Scholar
• Sadock BJ, Sadock VA, Ruiz P. Psychiatry Synopsis. 11th ed. China: Wolters Kluwer; 2015.
   Google Scholar
• Hoa T, Robbins E, Westwood M, Lezama D, Fishman M. Relapse prevention medications in community treatment for young adults with opioid addiction. Substance Abuse. 2016;37(3):392–397. doi:10.1080/08897077.2016.1143435
   Web of Science ®Google Scholar
• Spanish Agency of Medicines and Health Products [internet]. Madrid: Spanish agency of medicines and health products; 2012. Available from: http://www.aemps.gob.es. Accessed January 1, 2021.
   Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x
   PubMed Web of Science ®Google Scholar
• Sudakin D. Naltrexone: Not Just For Opioids Anymore. J Med Toxicol. 2016;12(1):71–75. doi:10.1007/s13181-015-0512-x
   PubMed Web of Science ®Google Scholar
• Brewer C, Streel E. Naltrexone implants: a real therapeutic advance both behavioral as well as pharmacological. Addictions. 2003;15(4):299–308.
   Google Scholar
• Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts with a total of 101 patients with a note on naltrexone blood levels. Addict Biol. 2003;8:211–217. doi:10.1080/1355621031000117446
   PubMed Web of Science ®Google Scholar
• Lee J, Friedmann P, Kinlock TW, Nunes E, Gordon M, O’Brien C. Extended-release naltrexone for opioid relapse prevention among opioid-dependent, criminal justice-involved adults. Drug Alcohol Depend. 2015;156(125). doi:10.1016/j.drugalcdep.2015.07.345
   Google Scholar
• Brewer C, Streel E. Recent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthood. Addictions. 2010;22(4):285–292.
   Google Scholar
• Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;2. doi:10.1002/14651858.CD006140.pub2
   Web of Science ®Google Scholar
• Gueorguieva R, Wu R, Krystal JH, Donovan D, O’Malley SS. Temporal patterns of adherence to medications and behavioral treatment and their relationship to patient characteristics and treatment response. Addict Behav. 2013;38(5):2119–2127. doi:10.1016/j.addbeh.2013.01.024
   Web of Science ®Google Scholar
• Vuoristo-Myllys S, Lahti J, Alho H, Julkunen J. Predictors of dropout in an outpatient treatment for problem drinkers including cognitive-behavioral therapy and the opioid antagonist naltrexone. J Stud Alcohol Drugs. 2013;74(6):894–901. doi:10.15288/jsad.2013.74.894
   Web of Science ®Google Scholar
• Witkiewitz K, Votaw VR, Vowles KE, Kranzler HR. Opioid misuse as a predictor of alcohol treatment outcomes in the combine study: mediation by medication adherence. Alcohol Clin Exp Res. 2018;42(7):1249–1259. doi:10.1111/acer.13772
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419–1427. doi:10.2147/DDDT.S55587
   PubMed Web of Science ®Google Scholar
• Savard J, Öberg KG, Chatzittofis A, Dhejne C, Arver S, Jokinen J. Naltrexone in compulsive sexual behavior disorder: a feasibility study of twenty men. J Sex Med. 2020;17(8):1544–1552. doi:10.1016/j.jsxm.2020.04.318
   PubMed Web of Science ®Google Scholar
• Kovanen L, Basnet S, Castrén S, et al. A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016;22:70–79. doi:10.1159/000435876
   PubMed Web of Science ®Google Scholar
• Olbrich S, Jahn I, Stengler K. Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring. Behav Cogn Psychother. 2019;47(5):622–627. doi:10.1017/S1352465819000213
   Web of Science ®Google Scholar
• Aboujaoude E, Salame W. Naltrexone: a pan-addiction treatment? CNS Drugs. 2016;30(8):719–733. doi:10.1007/s40263-016-0373-0
   PubMed Web of Science ®Google Scholar
• Sullivan M, Bisaga A, Pavlicova M, et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174(5):459–467. doi:10.1176/appi.ajp.2016.16050548
   PubMed Web of Science ®Google Scholar
• Cousins SJ, Crèvecoeur-MacPhail D, Kim T, Rawson RA. Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010–2015). J Subst Abuse Treat. 2017;85:78–83. doi:10.1016/j.jsat.2017.02.011
   Web of Science ®Google Scholar
• Cousins SJ, Radfar SR, Crèvecoeur-MacPhail D, Ang A, Darfler K, Rawson RA. Predictors of continued use of extended-released Naltrexone (XR-NTX) for opioid-dependence: an analysis of heroin and non-heroin opioid users in Los Angeles County. J Subst Abuse Treat. 2016;63:66–71. doi:10.1016/j.jsat.2015.12.004
   PubMed Web of Science ®Google Scholar
• Chaudhry ZA, Sultan J, Alam F. Predictors for retention in treatment with a UK community-based naltrexone program for opioid dependence. Psychiatrist. 2012;36(6):218–224. doi:10.1192/pb.bp.111.035063
   Google Scholar
• Streel E, Chenut C, Papageorgiou C, Verbanck P. DSM IV axis II traits can influence compliance to treatment with oral naltrexone: a preliminary study on 30 opiate dependent patients. Addict Behav. 2014;39(1):321–324. doi:10.1016/j.addbeh.2013.08.031
   Web of Science ®Google Scholar
• DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012;120(1–3):48–54. doi:10.1016/j.drugalcdep.2011.06.023
   Web of Science ®Google Scholar
• Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addictions. 2011;106(7):1309–1318. doi:10.1111/j.1360-0443.2011.03400.x
   PubMed Web of Science ®Google Scholar
• Dunn KE, Defulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol. 2013;21(1):74–83. doi:10.1037/a0030743
   PubMed Web of Science ®Google Scholar
• Dunn K, DeFulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychol Addict Behav. 2015;29(2):270–276. doi:10.1037/adb0000010
   Web of Science ®Google Scholar
• Williams AR, Barbieri V, Mishlen K, et al. Long‐term follow‐up study of community‐based patients receiving XR‐NTX for opioid use disorders. Am J Addict. 2017;26:319–325. doi:10.1111/ajad.12527
   Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129–137. doi:10.1176/appi.ajp.2018.17070732
   PubMed Web of Science ®Google Scholar
• Farabee D, Condon T, Hallgren K, McCrady B. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder. J Subst Abuse Treat. 2020;117:1–8. doi:10.1016/j.jsat.2020.108076
   Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, Berry MS, et al. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. J Subst Abuse Treat. 2018;85:38–44. doi:10.1016/j.jsat.2017.04.012
   Web of Science ®Google Scholar
• Haeny AM, Montgomery L, Burlew AK, et al. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. Addict Behav. 2020;110:106514. doi:10.1016/j.addbeh.2020.106514
   Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513. doi:10.1016/S0140-6736(11)60358-9
   PubMed Web of Science ®Google Scholar
• Walker JR, Korte JE, McRae-Clark AL, Hartwell KJ. Adherence across FDA-approved medications for alcohol use disorder in a veterans administration population. J Stud Alcohol Drugs. 2019;80(5):572–577. doi:10.15288/jsad.2019.80.572
   Web of Science ®Google Scholar
• Farhadian N, Moradi S, Zamanian MH, et al. Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review. Subst Abuse Treat Prev Policy. 2020;15:24. doi:10.1186/s13011-020-00266-6
   Web of Science ®Google Scholar
• Malone M, McDonald R, Vittitow A, et al. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON). Contemp Clin Trials. 2019;81:102–109. doi:10.1016/j.cct.2019.04.006
   PubMed Web of Science ®Google Scholar
• Lohit K, Kulkarni C, Galgali RB. Factors influencing adherence to anti-craving medications and drinking outcomes in patients with alcohol dependence: a hospital-based study. J Pharmacol Pharmacother. 2016;7(2):72–79. doi:10.4103/0976-500X.184770
   PubMed Web of Science ®Google Scholar
• Stoner SA, Arenella PB, Hendershot CS. Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders. PLoS One. 2015;10(4):e0124613. doi:10.1371/journal.pone.0124613
   Web of Science ®Google Scholar
• Dermody SS, Wardell JD, Stoner SA, Hendershot CS. Predictors of daily adherence to naltrexone for alcohol use disorder treatment during a mobile health intervention. Ann Behav Med. 2018;52(9):787–797. doi:10.1093/abm/kax053
   Web of Science ®Google Scholar
• Hendershot CS, Dermody SS, Wardell JD, Zaso MJ, Kennedy JL, Stoner SA. OPRM1 moderates daily associations of naltrexone adherence with alcohol consumption: preliminary evidence from a mobile health trial. Alcohol Clin Exp Res. 2020;44(4):983–991. doi:10.1111/acer.14300
   Web of Science ®Google Scholar
• Chokron Garneau H, Venegas A, Rawson R, Ray LA, Glasner S. Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders. J Subst Abuse Treat. 2018;85:34–37. doi:10.1016/j.jsat.2017.05.004
   Web of Science ®Google Scholar
• Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res. 2011;35(10):1804–1811. doi:10.1111/j.1530-0277.2011.01524.x
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Moore BA, Holt SR, et al. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: a Randomized-Controlled Trial. AIDS Behav. 2019;23(1):211–221. doi:10.1007/s10461-018-2241-z
   PubMed Web of Science ®Google Scholar
• Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community [published correction appears in Contemp Clin Trials. 2017 Jun;57:98]. Contemp Clin Trials. 2014;37(2):209–218. doi:10.1016/j.cct.2013.12.006
   PubMed Web of Science ®Google Scholar
• Stout RL, Braciszewski JM, Subbaraman MS, et al. What happens when people discontinue taking medications? Lessons from COMBINE. Addictions. 2014;109(12):2044–2052. doi:10.1111/add.12700
   Web of Science ®Google Scholar
• Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend. 2012;123(1–3):57–65. doi:10.1016/j.drugalcdep.2011.10.018
   Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addictions. 2013;108(9):1628–1637. doi:10.1111/add.12208
   PubMed Web of Science ®Google Scholar
• Hermes G, Hyman SM, Fogelman N, Kosten TR, Sinha R. Lofexidine in combination with oral naltrexone for opioid use disorder relapse prevention: a pilot randomized, double‐blind, Placebo‐Controlled Study. Am J Addict. 2019;28:480–488. doi:10.1111/ajad.12942
   Web of Science ®Google Scholar
• Busch AC, Denduluri M, Glass J, et al. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a Randomized Pilot Proof-of-Concept Study. Alcohol Clin Exp Res. 2017;41(7):1352–1360. doi:10.1111/acer.13410
   PubMed Web of Science ®Google Scholar
• Friedmann P, Wilson D, Hoskinson R, Poshkus M, Clarke J. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. J Subst Abuse Treat. 2018;85:45–48. doi:10.1016/j.jsat.2017.04.010
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Glass A, et al. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend. 2015;147:122–129. doi:10.1016/j.drugalcdep.2014.11.028
   PubMed Web of Science ®Google Scholar
• Brantley P, Holtyn A, deFulio A, et al. Effects of incentives for naltrexone adherence on opiate abstinence in heroin‐dependent adults. Addiction. 2017;112(5):830–837. doi:10.1111/add.13724
   Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction. 2017;112(5):830–837
   Web of Science ®Google Scholar